Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsWith over a decade of experience in phage display technology, Creative Biolabs can provide a series of antibody or peptide libraries that are available for licensing or direct screening. These ready-to-use libraries are invaluable resources for isolating target-specific binders for various research, diagnostic or therapeutic applications. Highlights
Creative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
Highlights
CD36 (Cluster of Differentiation 36) is a scavenger receptor expressed in many cell types, which is associated with various diseases, including infection, Alzheimer's disease, cancer, and metabolic diseases. As a transmembrane glycoprotein, CD36 contains multiple post-translational modification sites and can bind to a variety of ligands, such as thrombospondin-1 (TSP-1), apoptotic cells and fatty acids (FA). CD36 can promote tumor metastasis and treatment resistance by enhancing lipid uptake and FA oxidation. In addition, CD36 inhibits angiogenesis by binding to TSP-1, thereby inducing apoptosis or blocking the vascular endothelial growth factor receptor 2 (VEGFR2) pathway in tumor microvascular endothelial cells. At the same time, in tumor-associated immune cells, CD36-driven reprogramming and functions of lipid metabolism lead to tumor immune tolerance and cancer development. Therefore, CD36 is now considered to have great potential in cancer diagnosis and targeted therapy.
In view of the important role of CD36 in tumorigenesis, development, and metastasis, many preclinical studies and clinical trials on CD36 have been and are under way. Inhibition of CD36-mediated FA uptake is one of strategies for metastatic tumor treatment. Studies of targeting TSP-1 binding to CD36 have also made progress. Three modified TSR peptides (ABT-526, ABT-510, and ABT-898) have been found to be effective in animal experiments, and ABT-510 was even approved to enter Phase 2 clinical trial. In addition, TAX2, derived from CD47, induces the transformation of the binding target of TSP-1 from CD47 to CD36, resulting in anti-angiogenesis in tumors. Further research on CD36 will help explore new strategies for drug discovery and cancer treatment.
Creative Biolabs has developed a series of CD36 membrane protein products in different formats, including detergent, liposome, VLP, nanodisc, and SMALPs/Polymers to fit your requirements. They show very good performance in functional studies, antibody development, drug discovery, structure determination (NMR spectroscopy, crystallization, Cryo-EM), etc.
References
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
